Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income (2016 - 2025)

Vanda Pharmaceuticals' Net Income history spans 16 years, with the latest figure at -$141.2 million for Q4 2025.

  • For Q4 2025, Net Income fell 2774.86% year-over-year to -$141.2 million; the TTM value through Dec 2025 reached -$220.5 million, down 1066.53%, while the annual FY2025 figure was -$220.5 million, 1066.53% down from the prior year.
  • Net Income for Q4 2025 was -$141.2 million at Vanda Pharmaceuticals, down from -$22.6 million in the prior quarter.
  • Across five years, Net Income topped out at $9.7 million in Q2 2021 and bottomed at -$141.2 million in Q4 2025.
  • The 5-year median for Net Income is -$1.1 million (2023), against an average of -$9.9 million.
  • The largest annual shift saw Net Income surged 1675.31% in 2021 before it tumbled 3986.13% in 2024.
  • A 5-year view of Net Income shows it stood at $7.1 million in 2021, then decreased by 3.35% to $6.9 million in 2022, then plummeted by 134.84% to -$2.4 million in 2023, then crashed by 104.67% to -$4.9 million in 2024, then plummeted by 2774.86% to -$141.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Net Income are -$141.2 million (Q4 2025), -$22.6 million (Q3 2025), and -$27.2 million (Q2 2025).